biotech – Asia Tab

ACN Newswire

Novotech Acquires European CRO, Strengthens Global Operations

12 1 月, 2023

SINGAPORE, Jan 12, 2023 - (ACN Newswire via SEAPRWire.com) - Novotech announced today the acquisition of EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent. The acquisition is part of Novotech's global expansion program. EastHORN was established in 2004 and has over 250 employees.The acquisition means biotech clients can access Novotech's unique and unparalleled suite of early to late-phase CRO services across Europe and the US, with a specialist focus on Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials.Novotech CEO Dr. John Moller said: "This acquisition is a strategic move to further expand our CRO operations and provide biotech clients with in-country expertise across Asia-Pacific, North America, and Europe to deliver their global drug development programs. EastHORN and Novotech have been working together for many years and we share a culture of clinical excellence in biotech drug development. EastHORN which is retaining its brand, is now a Novotech company and will be integrated into our systems and processes so clients benefit from working with one CRO globally. Clients can now access our exceptional European infrastructure, local knowledge, site relationships and access to diverse patient populations."EastHORN Executive Chairman Iain Gordon said: "I first started working on clinical projects with Novotech 15 years ago and have always been impressed by the quality of their services and their client-focused approach. EastHORN has been working closely with Novotech for over a decade now and have many friends within the Novotech team. This is a natural next step for our group and my colleagues and I are excited to become part of Novotech's global operations to support biotech clients' clinical programs. In particular, we can now offer our clients access to Novotech's team of experts across Asia-Pacific and the US including project management, regulatory, clinical, medical and biometrics, while our team's European expertise can advance clinical development in Europe for Novotech clients. We work with similar-sized biotechs and small to mid-size pharma companies and have experience across the same therapeutic areas, so this is an excellent cultural and strategic fit."Novotech has decades of biotech drug development experience, exceptional site and investigator relationships, access to vast patient populations, and a project management approach focused on problem-solving, ownership and flexibility. Consistent investment in advanced training and technology combines to deliver an exceptional full-service biotech CRO solution.Novotech has recently been recognised with significant CRO awards including the Asia-Pacific Biotech CRO of the Year by Frost & Sullivan, benchmarked as a top 10 CRO among the world's leading CROs, a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.About Novotech Novotech is the leading Asia-Pacific centred biotech CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. Novotech is well-positioned to serve biotech clients conducting clinical trials in Asia-Pacific, the US, and Europe. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

Avance Clinical Celebrates GlobalReady Success as more than 40 Biotech Clients Enter Program

11 1 月, 2023

SAN FRANCISCO, CA, Jan 11, 2023 - (ACN Newswire via SEAPRWire.com) - More than 40 biotech clients are now taking advantage of Avance Clinical's GlobalReady program which delivers streamlined clinical development from early phase in Australia expanding to sites in North America for later phases. All with the one CRO and dedicated teams across both regions.Avance Clinical made the announcement at Biotech Showcase 2023 where the team is taking meetings via PartnershipOne. "Given this successful early adoption of GlobalReady we are expecting more than half of our biotech clients to join the program within the next six months, said Avance Clinical CEO Yvonne Lungershausen.GlobalReady biotech clients are primarily biotechs from the US and Asia, with an increasing number expected from Europe over the next few months.Avance Clinical is the leading Australian-based biotech CRO with US operations, which has been recognized by Frost & Sullivan for the past 3 years with the prestigious CRO Leadership Award.CEO Yvonne Lungershausen said: "These biotech clients are already benefiting from our expansion into North America and GlobalReady. The GlobalReady model is designed to extend biotechs' investments so they can achieve greater clinical development milestones with reduced spend, all with the assurance of FDA-accepted data. GlobalReady gives our biotech clients conducting their early phase studies in Australia and New Zealand a seamless journey into the US to continue their clinical development programs, retaining the same high-quality CRO, which reduces time and cost and delivers quality FDA-accepted data. In addition, the attractive 43.5% rebate on clinical spend in Australia, offers our clients the opportunity to utilize our North American operations expertise and team, whilst maintaining services in Australia to maximize their rebate potential. We often point to the fact that there are currently more than 280 Phase III global trials that have conducted their Phase I study in Australia, which again demonstrates Australian data acceptability with the FDA and other major regulatory authorities."This seamless GlobalReady journey is designed for success whereby biotechs can:- Take advantage of the Australian early-phase clinical trial landscape (No IND and 43.5% tax rebate)- Transition or expand into North America for later phases - without changing CROs (retain study knowledge and processes/team)- Seamlessly operationalize global dose-escalation and dose-expansion trials across the two regions- Harness significant speed and cost advantages- Be assured of quality data - transferable and readily acceptable by the FDA and other regulatory authorities"We have shown, with our high growth and industry-leading repeat business rates that our focus on gold standard technology paired with solution-orientated clinical experts is the mix our biotech clients need for clinical success," commented Yvonne Lungershausen.According to Frost & Sullivan as part of the independent analyst review of the company for the CRO Award: "Avance Clinical remains a trusted partner, earning a reputation for delivering the overall best in the CRO industry. With its strong overall performance, Avance Clinical earns Frost & Sullivan's 2022 Asia-Pacific Customer Value Leadership Award in the contract research organization industry."Find out more:- Learn about the Australian Advantage here https://www.avancecro.com/the-australian-advantage/- Learn about the GlobalReady model here https://www.avancecro.com/avance-clinical-north-america-operations/- For more information about the benefits of running your next study with Avance Clinical contact us: enquiries@avancecro.comAbout Avance ClinicalAvance Clinical is the largest premium full-service Australian and US CRO delivering quality clinical trials, with globally accepted data, in Australia, New Zealand and the US for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services. https://www.avancecro.com/Frost & Sullivan AwardsAvance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past three years, has been providing CRO services in the region for more than 24 years.Pre-clinical through to Phase 1 and 2Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes. With experience across more than 110 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.TechnologyAvance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, IBM Watson and Medrio are just some of the technology partners.Media Contact: Avance ClinicalKate Thompsonmedia@avancecro.com Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

China Biotech Services subsidiary AMDL nominated as Top Clinical Laboratory Services Company in APAC 2022 and receives CAP Accreditation Certificate

10 1 月, 2023

HONG KONG, Jan 10, 2023 - (ACN Newswire via SEAPRWire.com) - China Biotech Services Holdings Limited (the "Group"; stock code: 8037. HK) has announced that its subsidiary, Asia Molecular Diagnostics Laboratory (AMDL), has been nominated as the Top Clinical Laboratory Services Company in APAC 2022 and has received the College of American Pathologists (CAP) Accreditation Certificate for providing next-generation sequencing (NGS) Oncology clinical testing services. With world-leading NGS-based clinical testing products and services for oncologists and a high-standard molecular-level clinical laboratory, and as the sole distributor of Pillar Biosciences products in Asia, it's no surprise that AMDL has been named one of the industry's Top Clinical Laboratory Services Companies in APAC 2022 by Life Sciences Review. In addition, AMDL has recently received the Accreditation Certificate from CAP, which is recognized as one of the industry's leaders in medical laboratory quality assurance. It has developed detailed checklists for all aspects of clinical laboratory disciplines and has strict requirements for laboratory quality standards. AMDL obtaining the authoritative certification from CAP proves that the company has reached an advanced level in terms of quality, management mode, testing accuracy and other aspects.By leveraging next-generation sequencing (NGS) technology and FDA-approved companion diagnostic (CDx), namely the oncoReveal(TM) Dx Lung and Colon Cancer Assay and MiSeqDx developed by Pillar Biosciences, AMDL will provide precision diagnostic tests for the qualitative detection of somatic mutations in DNA derived from lung and colon cancer tumors. Working toward CAP accreditation, the AMDL platform can offer a simplified and standalone testing workflow that helps local healthcare professionals, oncologists, and researchers obtain results in seven to nine working days, significantly reducing the overall timeline. The CAP certification also provides a good endorsement for AMDL to promote the test kit in Hong Kong and Asia on a large scale, which is conducive to the rapid commercialization of the test kit and brings new achievements to China Biotech Services.About China Biotech Services Holdings (Stock Code: 8037.HK)China Biotech Services Holdings Limited is listed on GEM of Hong Kong Stock Exchange and was included in MSCI Hong Kong Micro Cap Index in May 2018. The Group focuses on two main areas, namely, precision diagnostics and cancer treatments. Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

Novotech 是 Biotech Showcase 2023 的金牌赞助商

20 12 月, 2022

SYDNEY, AU, Dec 20, 2022 - (亚太商讯 via SEAPRWire.com) - 以亚太地区为中心的生物技术专家 CRO Novotech很荣幸成为 Biotech Showcase 2023 的金牌赞助商。Novotech 首席执行官 John Moller 博士以及来自 Novotech 美国和亚太团队的专家将出席该会议。可以通过 PartneringOne 门户安排会议。 https://informaconnect.com/biotech-showcase/partnering/ Novotech 将分享亚太地区加快临床试验的优势，生物技术公司可以利用 Novotech 庞大的患者群体、强大的本地监管知识、广泛的站点和 KOL 网络以及数据质量的声誉。在亚太地区，Novotech 与主要医学研究机构签订了 50 多项领先的合作伙伴协议，为赞助商提供独家优惠。以亚太地区为中心的生物技术专家 CRO Novotech 表示，GlobalData 和 Novotech 最新发布的行业研究报告发现，近 50% 的新试验都在亚太地区进行。根据题为《全球生物技术现状：机遇所在》的新出版物，对亚太地区试验地点的需求强劲，2021 年启动的 27,000 多项临床试验中，近一半在亚太地区设有地点。数据显示，近12,900 项新试验的地点位于亚太地区。在这里下载报告 https://novotech-cro.com/whitepapers/state-global-biotech-landscape-where-opportunities-lie 该报告还指出，亚太地区拥有超过 6,772 个试验点，每个试验点平均覆盖 21.36 亿人，该地区有相当大的未充分利用的能力，为该地区的跨国试验提供了增长机会。本月，Novotech 因其在亚太地区合同研究组织行业的最佳实践而荣获 2022 年 Frost & Sullivan 年度公司奖。自 2006 年以来，Novotech 一直是 Frost & Sullivan 亚太最佳实践奖的获得者。Frost & Sullivan 表示：“我们的方法涉及在整个价值链中部署最佳实践和战略分析。在此背景下，Frost & Sullivan 认可了 Novotech 的宝贵成就。 Novotech 以强大的领导力为重点，将以客户为中心的战略与最佳实践实施相结合，以满足全球药物开发市场未满足的需求。从可行性评估到监管提交支持、数据管理、医疗监测和项目管理，该公司为其生物技术客户提供 360 度全方位的药物开发方法。”Novotech 最近还为考虑在中国进行临床研究以及全球监管批准所需的相关流程的生物技术公司制作了一份新出版物。Novotech 可以提供专门设计用于支持美国 FDA 批准流程的相关监管知识和药物开发途径，避免延误和额外费用。该报告详细介绍了生物技术的监管要求，包括NDA和IND流程，以及成功获得USFDA批准途径的美国前研究指南。Novotech 在中国和美国拥有经验丰富的临床团队，可以提供相关的监管知识和药物开发途径，专门为支持美国 FDA 的审批流程而设计，避免延误和额外成本。在此处下载白皮书 https://novotech-cro.com/whitepapers/china-biotech-landscape-opportunities-china-and-path-usfda-approval Novotech 最近被评为世界领先合同研究组织中的前十名合同研究组织，是著名的 Scrip 奖的决赛入围者，并且刚刚获得了基因与细胞治疗卓越奖。关于Novotech健康控股 - https://novotech-cro.comNovotech 是国际公认的具有全球执行能力的领先的以亚太地区为中心的CRO。 Novo-tech 是一家CRO，拥有综合实验室、I 期设施和药物开发咨询服务。积累了超过3,700个临床前和临床项目的经验，包括I期至IV期临床试验和生物等效性研究。Novotech具有明显优势，可以为在亚洲及美国进行临床试验的生物制药客户提供服务。Novotech 在 13 个地区的办事处拥有超过 2,500 名员工。https://novotech-cro.com/contact 媒体联系人David JamesE: communications@novotech-cro.com 澳大利亚: +61 2 8218 2144美国: +1 415 951 3228亚洲: +65 3159 3427 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

ACN Newswire

Led by Legend Capital, GS Biotech Completes Nearly CNY100 million Pre-A Round Financing

9 12 月, 2022

HONG KONG, Dec 9, 2022 - (ACN Newswire via SEAPRWire.com) - Recently, Zhongke Guosheng (Hangzhou) Technology Co., Ltd (hereinafter referred to as "GS Biotech") officially announced the completion of its nearly CNY100 million pre-A round financing, led by Legend Capital. The proceeds will be mainly used for the capacity expansion of core pipeline products 5-hydroxymethylfurfural (HMF), 2,5-furandicarboxylic acid (FDCA) and 2,5-tetrahydrofuran dimethanol (THFDM), and the continuous development of downstream derivatives.Founded in 2021 with the vision of "Biomass Change Lives", GS Biotech is a bio-based material and R&D company dedicated to building a bio-based material industry chain. The members of its founding team graduated from the Dalian Institute of Chemical Physics, Chinese Academy of Sciences, and have nearly 20 years of research foundation and industrialization experience in the fields of biomass catalytic conversion and furan-based material design and development. At present, the R&D team building has also been completed from biomass, derivatives to polymers, which ensures the cutting-edge of the company's product development and the availability of end products.According to Dr. John Zhang, CEO of GS Biotech, the company has taken the development model of promoting the "two-wheel drive" of the dual track as an important strategic direction. On the one hand, the company has completely solved the problems of HMF cost and raw material sources; its original HMF continuous production process, which completed the verification of multi-dimensional cost reduction measures, has greatly reduced the production cost and effectively improved the efficiency, and it is expected that the production cost of HMF will be controlled within RMB10,000 per ton in the future three years from the extraction of non-grain raw material sources to the iterative path of the production process and to the planning of expanding production capacity. Meanwhile, the company has also reserved more than 20 kinds of high-value-added monomers and is simultaneously promoting the verification of the application of each monomer in the terminal market. Moreover, GS Biotech established a joint venture, Xinshengtai Materials, with an AI-powered drug R&D unicorn company XtalPi Inc to focus on using AI technology to accelerate the reverse design of derivatives and improve the development efficiency of downstream derivatives to further accelerate its high-efficiency and accurate market development process.On the other hand, the company has also made significant progress in the design, R&D and industrialization of degradable new materials. The new biodegradable plastic PEOX, another important pipeline of the company, has completed the 150L pilot scale experiment and obtained market terminal verification. The performance indicators of PEOX can be compared with PGA and the price of the terminal product will be approximately RMB10,000/ton after the large-scale production. With the special performance of the product and the support of policies, many leading enterprises in the industry are negotiating with the company to sign an underwriting agreement to apply PEOX in the field of disposable packagings such as agricultural mulch, plastic bags, straws, and lunch boxes.Legend Capital said: "Under the background of China's strategy in carbon peaking and carbon neutrality and the pursuit of sustainable energy development, petroleum-based chemical materials will gradually be replaced by bio-based materials, which are produced from sustainable resources. HMF is an important bio-based platform compound with great potential for downstream derivatives. GS Biotech has pioneered the HMF continuous production process globally and realized the large-scale and low-cost production of HMF. It has opened the entire industry chain from upstream core monomers to terminal applications and innovatively introduced AI and high-throughput machine synthesis technology into the development of downstream derivative products. The core team of GS Biotech graduated from the Dalian Institute of Chemical Physics of the Chinese Academy of Sciences. With nearly 20 years of research foundation and industrialization experience in the field of biomass catalytic conversion, GS Biotech has shown strong capabilities in continuous R&D, production management, and resource integration. Legend Capital has long focused on technology investments linked to carbon peaking and carbon neutrality, and we look forward to working with GS Biotech to promote technological change in the field of bio-based materials."As an interdisciplinary subject of information science, life science and material science, synthetic biology and bio-based materials have always been the direction that Legend Capital has paid close attention to in the field of carbon-neutral technology investment. Legend Capital's investments in the carbon-neutral field focus on energy decarbonization, vehicle electrification/intelligence, synthetic biology, etc. Energy decarbonization includes photovoltaic, wind power, and smart grid; vehicle electrification/intelligence includes lithium battery vehicles, hydrogen fuel cell vehicles, battery recycling and others; in the field of synthetic biology and bio-based materials, Legend Capital has invested in many outstanding companies such as Giant Biogene (02367.HK), GS Biotech, Huili Biotech, and Tidetron Bioworks Technology.About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea.It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

The Biotech Landscape Webinar: Market Trends, Priorities, Predictions, and Pathways to FDA Approval

17 10 月, 2022

SYDNEY, AU, Oct 17, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO, and Endpoints News present a webinar for biotechs considering the clinical research opportunities in Asia Pacific and the regulatory pathways to achieving FDA approval.Novotech has operations across Asia Pacific and the US offering a unique and unparalleled suite of CRO services for early to late phase biotech clinical research.The webinar features regulatory affairs and investment leaders from North America and Asia Pacific who will discuss:- why biotech companies are increasingly exploring clinical opportunities in Asia Pacific to generate diverse, globally accepted clinical trial data- what actionable strategies can be implemented to leverage Asia Pacific's recruitment potential to accelerate your clinical development- how Phase 1 data from Australia is acceptable to the FDA and can be used to launch global drug development programs- deep insight into processes for designing and delivering a robust clinical program- biotech challenges and opportunities in the post-COVID environment with a focus on global investments and drug pipelinesRegister for the webinar here https://webinars.endpts.com/the-biotech-landscape-market-trends-priorities-predictions-and-pathways-to-fda-approval/October 18, 20221:00 pm - 2:00 pm EDTThe industry leaders presenting include:- Yi Larson, Chief Financial Officer of LianBio. Formerly Executive Vice President and Chief Financial Officer at Turning Point Therapeutics, Inc., and Goldman Sachs & Co. LLC, Managing Director of Healthcare Investment Banking- Kasey Kime, Director of Regulatory Affairs for Novotech's in-house consulting group, BioDesk- Dr. Jeanne M. Novak, President and CEO of CBR International Corp., a full-service product, clinical, and regulatory strategy group- Dr. Fred Cohen, a Co-Founder and Chairman of Monograph Capital Partners. He is also a Co-Founder and Senior Managing Director at Vida Ventures.Novotech has decades of biotech drug development experience, exceptional site and investigator relationships, access to vast patient populations, and a project management approach focused on problem-solving, ownership and flexibility. Consistent investment in advanced training and technology systems combine to deliver a specialist full-service biotech CRO solution.Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.About Novotech Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

Avance Clinical Wins International Health Award for Biotech CRO Services

28 9 月, 2022

SYDNEY, AU, Sep 28, 2022 - (ACN Newswire via SEAPRWire.com) - Avance Clinical, the leading Australian-based biotech CRO with US operations has won the South Australian Premier's Export Awards - International Health category. The award recognises excellence in clinical services exports.Avance Clinical CEO Yvonne LungershausenThe Premier of South Australia Peter Malinauskas, and Minister for Trade and Investment Nick Champion, presented the Premier's Export Awards to Avance Clinical CEO Yvonne Lungershausen at the awards industry event today. This follows Avance Clinical's selection as finalist for the Informa Pharma Intelligence Awards 2022 Best Contract Research Organization in APAC. Avance Clinical, which is backed by global private equity firm The Riverside Company, recently acquired a leading CRO in North America to expand services and offer their biotech clients US sites for later phase studies. CEO Yvonne Lungershausen said Avance Clinical is now the leading Australian-based biotech CRO with US operations. "We are honoured to be selected for the award. We are a major employer with more than 220 staff and we bring significant biotech clinical research business into South Australia and Australia. Clinical research is a high-value export that keeps our medical, research, and biopharma sectors at the forefront of international knowledge and innovation. The majority of our clients are from North America, the EU, and Asia so we really are an internationally-focused organisation. Avance Clinical has a global reputation for agile clinical solutions to support accelerated clinical development for our international biotech clients and we are very proud of our growth and success in recent years."The company provides global regulatory standard clinical research services across all phases to the international biopharma industry. Avance Clinical is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) for vaccines and GMO therapies clinical trials."We have shown, with our high growth and industry-leading repeat business rates that our focus on gold standard technology paired with solution-orientated clinical experts is the mix our biopharma clients require in this fast-moving, competitive and high-stakes sector," said Lungershausen.Avance Clinical has been recognised for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award.Find out more:- Learn about the Australian Advantage here https://www.avancecro.com/the-australian-advantage/- Read more about Avance Clinical's cell and gene therapy capabilities here www.avancecro.com/avance-clinical-featured-in-endpoints-news-on-cell-gene-therapy-capabilities/- For more information about the benefits of running your next study with Avance Clinical contact us: enquiries@avancecro.comAbout Avance ClinicalAvance Clinical is the largest premium full-service Australian CRO delivering quality clinical trials, with globally accepted data, in Australia and New Zealand for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.Frost & Sullivan AwardsAvance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past two years, has been providing CRO services in the region for more than 24 years.Pre-clinical through to Phase 1 and 2Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes. With experience across more than 110 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.TechnologyAvance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, IBM Watson and Medrio are just some of the technology partners.Media Contacts: Avance ClinicalChris Thompsonmedia@avancecro.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

Avance Clinical Sponsors Biotech Company of the Year Awards at Informa Pharma Intelligence Awards 2022

29 8 月, 2022

ADELAIDE, AUS, Aug 29, 2022 - (ACN Newswire via SEAPRWire.com) - Avance Clinical, the leading Australian CRO for international biotechs, is sponsoring two awards - Biotech Company of the Year Private and Public - at the Informa Pharma Intelligence Awards 2022 and is also a finalist for the Best Contract Research Organization in APAC.The Biotech Company of the Year awards recognize achievements including "moving the business from an early stage to a more mature company, signing a transformative deal, taking its first or a major new product towards the market, or raising significant new funds".CEO Yvonne Lungershausen and Chief Strategy Officer Ben Edwards are attending the awards night and hosting a table for biotech clients in Japan next week. Avance Clinical, which is backed by global private equity firm The Riverside Company, is in the process of regional and international expansion plans.Along with Avance Clinical, the finalists for the Best Contract Research Organization APAC are:- Calyx- CMIC Group- EPS- ICON- Parexel- Syneos HealthAvance Clinical's CEO Yvonne Lungershausen said: "Avance Clinical is extremely pleased to be sponsoring these biotech awards. We are the CRO for international biotechs and this collaboration with Informa Pharma Intelligence shows our ongoing support and investment for the biotech industry."The finalists for Biotech Company of the Year - Private:- ARTham Therapeutics- Chordia Therapeutics- Cuorips- Heartseed- Prism BioLab- Rebirthel- ReboRNA Biosciences- TMSThe finalists for Biotech Company of the Year - Public:- NanoCarrier- Rakuten Medical (Rakuten Group Inc.'s equity accounted affiliate)- Sosei Heptares- Stella Pharma- StemCell Institute"In addition, we are extremely honored to be selected as a finalist for the prestigious award Best Contract Research Organization in APAC. It is a credit to our customer-focused team for delivering world-leading CRO services for biotechs which has been recognized by the Informa Pharma Intelligence award judges. Avance Clinical has a global reputation for agile clinical solutions to support accelerated clinical development for our international biotech clients. We are very proud of our growth and success in recent years."According to Informa Pharma Intelligence, this Award is to recognize CROs that provide full or specialist services to their clients and which have an office in either in Japan or the Asia region including Australia. Judging considers the quality of services and relationships built with clients and pays particular attention to the innovative patient recruitment strategies the CRO has brought to the table. The award is based on achievements in the 2021 calendar year.Core areas judged include:- The particular capabilities and strengths the CRO offers- How the company has delivered results that exceed sponsor expectations- Innovations in patient recruitment strategy has the CRO brought to its partner- How it has improved its performance, for example, in its quality of data, timelines and transparency- The steps the company is taking towards streamlining data collection and reportingTo find out more please visit: https://pharmaintelligence.informa.com/events/awards/japan-awards-2022/shortlist-2022Avance Clinical is the Australian-owned CRO that provides global regulatory standard clinical research services across all phases to the local and international biopharma industry. The company is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) which has allowed it to expand into clinical trials for vaccines and GMO therapies."We have shown, with our high growth and industry-leading repeat business rates that our focus on gold standard technology paired with solution-orientated clinical experts is the mix our biopharma clients require in this fast-moving, competitive and high-stakes sector," said Lungershausen.Avance Clinical has been recognised for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award.Find out more:- Learn about the Australian Advantage here https://www.avancecro.com/the-australian-advantage/- Read more about Avance Clinical's cell and gene therapy capabilities here www.avancecro.com/avance-clinical-featured-in-endpoints-news-on-cell-gene-therapy-capabilities/ - For more information about the benefits of running your next study with Avance Clinical contact us: enquiries@avancecro.com About Avance ClinicalAvance Clinical is the largest premium full-service Australian CRO delivering quality clinical trials, with globally accepted data, in Australia and New Zealand for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.Frost & Sullivan AwardsAvance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past two years, has been providing CRO services in the region for more than 24 years.Pre-clinical through to Phase 1 and 2Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes. With experience across more than 110 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.TechnologyAvance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, IBM Watson and Medrio are just some of the technology partners.Media Contacts: Avance ClinicalChris Thompsonmedia@avancecro.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)